Assessment of threatened status, phytochemical composition and biological properties of three Aconitum species from Kashmir Himalaya - India

Genus Aconitum (Ranunculaceae) is represented by 6–8 species from Kashmir Himalaya.  Traditionally Aconitum species are used to treat a wide array of diseases, but their ethnopharmacological validation and phytochemistry are hitherto unreported from Kashmir Himalaya. The present study was undertaken to bring insights into the traditional use and distribution pattern of three Aconitum species from the region. An ethnobotany-directed approach was employed to study the conservation status of three Aconitum species. Their phytochemical profiles and biological properties were screened under in vitro conditions. Folin–ciocalteu and Aluminium chloride assays were employed to measure their total phenolic and total flavonoid contents, respectively. Plant extracts were evaluated for antioxidant, antimicrobial and anti-inflammatory activities. Three Aconitum species, viz. Aconitum heterophyllum Wall. ex Royle, Aconitum violaceum Jacquem. ex Stapf and Aconitum chasmanthum Stapf. ex Holmes showed dwindling conservation status in Kashmir Himalaya. Aconitum extracts showed significant variations in total phenolic and flavonoid contents. Antioxidant activity of Aconitum chasmanthum methanolic extract was studied to be comparatively higher (80.115%). Aconitum chasmanthum DCM & methanolic extracts showed a good MIC value of 0.125 mg/ml against Candida albicans and Streptococus pyogenes, respectively. The percent inhibition of NLRP inflammasome was found significant in Aconitum violaceum ethyl acetate extract (74.61%). The present study revealed that Aconitum species are constantly declining at least in investigated habitats of Kashmir Himalaya and hence need strategic conservation planning. The results also emphasized the utility of Aconitum species as an antioxidant, antimicrobial and anti-inflammatory agent that could be used to manage various health problems

Characterization of ES10 lytic bacteriophage isolated from hospital waste against multidrug-resistant uropathogenic E. coli

Escherichia coli is the major causative agent of urinary tract infections worldwide and the emergence of multi-drug resistant determinants among clinical isolates necessitates the development of novel therapeutic agents. Lytic bacteriophages efficiently kill specific bacteria and seems promising approach in controlling infections caused by multi-drug resistant pathogens. This study aimed the isolation and detailed characterization of lytic bacteriophage designated as ES10 capable of lysing multidrug-resistant uropathogenic E. coli. ES10 had icosahedral head and non-contractile tail and genome size was 48,315 base pairs long encoding 74 proteins. Antibiotics resistance, virulence and lysogenic cycle associated genes were not found in ES10 phage genome. Morphological and whole genome analysis of ES10 phage showed that ES10 is the member of Drexlerviridae. Latent time of ES10 was 30 min, burst size was 90, and optimal multiplicity of infection was 1. ES10 was stable in human blood and subsequently caused 99.34% reduction of host bacteria. Calcium chloride shortened the adsorption time and latency period of ES10 and significantly inhibited biofilm formation of host bacteria. ES10 caused 99.84% reduction of host bacteria from contaminated fomites. ES10 phage possesses potential to be utilized in standard phage therapy

Diagnosis of enteric fever in the emergency department: a retrospective study from Pakistan

Background:Enteric fever is one of the top differential diagnoses of fever in many parts of the world. Generally, the diagnosis is suspected and treatment is initiated based on clinical and basic laboratory parameters.Aims: The present study identifies the clinical and laboratory parameters predicting enteric fever in Patients visiting the emergency department of a tertiary care hospital in Pakistan.Methods:This is a retrospective chart review of all adult Patients with clinically suspected enteric fever admitted to the hospital through the emergency department during a 5-year period (2000-2005).Results:A total of 421 emergency department Patients were admitted to the hospital with suspected enteric fever. There were 53 cases of blood culture-positive enteric fever and 296 disease-negative cases on culture. The mean age in the blood culture-positive group was 27 years (SD: 10) and in the group with negative blood culture for enteric fever, 35 years (SD: 15) with a male to female ratio of 1:0.6 in both groups. Less than half (48%) of all Patients admitted with suspected enteric fever had the discharge diagnosis of enteric fever, of which only 13% of the Patients had blood culture/serologically confirmed enteric fever. None of the common clinical and laboratory parameters differed between enteric fever-positive Patients and those without it.Conclusion:Commonly cited clinical and laboratory parameters were not able to predict enteric fever

Antiviral potential of anthraquinones from Polygonaceae, Rubiaceae and Asphodelaceae: Potent candidates in the treatment of SARS-COVID-19, A comprehensive review

Medicinal plants are being used as an alternative source of health management to cure various human ailments. The healing role is attributed to the hidden dynamic groups of various phytoconstituents, most of which have been recorded from plants and their derivatives. Nowadays, medicinal plants have gained more attention due to their pharmacological and industrial potential. Aromatic compounds are one of the dynamic groups of secondary metabolites (SM) naturally present in plants; and anthraquinones of this group are found to be attractive due to their high bioactivity and low toxicity. They have been reported to exhibit anticancer, antimicrobial, immune-suppressive, antioxidant, antipyretic, diuretic and anti-inflammatory activities. Anthraquinones have been also shown to exhibit potent antiviral effects against different species of viruses. Though, it has been reported that a medicinal plant with antiviral activity against one viral infection may be used to combat other types of viral infections. Therefore, in this review, we explored and highlighted the antiviral properties of anthraquinones of Polygonaceae, Rubiaceae and Asphodelaceae families. Anthraquinones from these plant families have been reported for their effects on human respiratory syncytial virus and influenza virus. They are hence presumed to have antiviral potential against SARS-CoV as well. Thus, anthraquinones are potential candidates that need to be screened thoroughly and developed as drugs to combat COVID-19. The information documented in this review could therefore serve as a starting point in developing novel drugs that may help to curb the SARS-COVID-19 pandemic

Efficacy of Ciprofloxacin for Treatment of Cholera Associated with Diminished Susceptibility to Ciprofloxacin to Vibrio cholerae O1.

We identified a poor clinical response to treatment of cholera with a single 1 g dose of ciprofloxacin, a standard treatment for cholera.To determine reasons for the poor response and better therapeutic approaches we examined the minimal inhibitor concentration (MIC, n = 275) and disc-diffusion zone sizes (n = 205) for ciprofloxacin and nalidixic acid of V. cholerae O1 strains isolated in Bangladesh from 1994 to 2012, and reexamined data from 161 patients infected with Vibrio cholerae O1 recruited in four clinical trials who received single- or multiple-dose ciprofloxacin for treatment of cholera and compared their clinical response to the V. cholerae O1 susceptibility.Although all 275 isolates of V. cholerae O1 remained susceptible to ciprofloxacin using standard MIC and disc-diffusion thresholds, the MIC90 to ciprofloxacin increased from 0.010 in 1994 to 0.475 μgm/ml in 2012. Isolates became frankly resistant to nalidixic with the MIC90 increasing from 21 μgm/ml in 1994 to >256 μgm/ml and 166 of 205 isolates from 1994 to 2005 being frankly resistant using disc-diffusion testing. Isolates resistant to nalidixic acid by disc-diffusion testing had a median ciprofloxacin MIC of 0.190 μgm/ml (10th-90th centiles 0.022 to 0.380); nalidixic acid-susceptible isolates had a median ciprofloxacin MIC of 0.002 (0.002 to 0.012).The rate of clinical success with single-dose ciprofloxacin treatment for nalidixic acid-susceptible strains was 94% (61 of 65 patients) and bacteriologic success 97% (63/65) compared to 18% (12/67) and 8% (5/67) respectively with nalidixic acid-resistant strains (P<0.001 for both comparisons). Multiple-dose treatment with ciprofloxacin had 86% and 100% clinical and bacteriologic success rates respectively in patients infected with nalidixic acid-susceptible strains of V. cholerae O1 compared to clinical success 67% and bacteriologic success 60% with nalidixic acid-resistant strains.Single-dose ciprofloxacin is not effective for treating cholera caused by V. cholerae O1 with diminished susceptibility to ciprofloxacin, and nalidixic acid disc-diffusion testing effectively screens for such isolates

Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.

<p>Values are median (25^th–75^th centile) unless noted.</p><p>* Based on weight discharge</p><p>Clinical and bacteriologic response to single-dose or multiple-dose ciprofloxacin therapy in patients infected with nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.</p

Randomized controlled trials from which 161 adult patients infected with <i>V</i>. <i>cholerae</i> O1;treated with ciprofloxacin and completed 5day study were included in this analysis.

<p>There were 580 patients in total in these four studies, of whom 161 (28%) were infected with <i>V</i>.<i>cholerae</i> O1; treated with ciprofloxacin and completed 5 day study</p><p>Randomized controlled trials from which 161 adult patients infected with <i>V</i>. <i>cholerae</i> O1;treated with ciprofloxacin and completed 5day study were included in this analysis.</p

Admission characteristics and response to ciprofloxacin therapy in 161 patients infected with nalidixic acid-susceptible and nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.

<p>Values are median (25^th, 75^th centiles) unless noted</p><p>* Based on disc-diffusion method</p><p>^‡ Based on discharge weight</p><p>Admission characteristics and response to ciprofloxacin therapy in 161 patients infected with nalidixic acid-susceptible and nalidixic acid-resistant strains of <i>V</i>. <i>cholerae</i> O1.</p